ClinicalTrials.gg
CompletedNCT04251910TRANQUILITYUpdated Aug 11, 2026Results posted

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

A Phase 1/2 interventional study of Sublingual film containing Dexmedetomidine and Sublingual Placebo Film in Agitation,Psychomotor and Dementia, sponsored by BioXcel Therapeutics Inc. Completed at 5 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.

Enrollment
12th of 32
100 · median 73
Started
2019
with 1 other
Phase 1/2
Only one
of the 32
Registered
16th of 32
by date
Lead sponsor
11 of 32
BioXcel Therapeutics Inc

Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 16th registered.

Psychomotor Agitation

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

Browse Psychomotor Agitation studies →

Open to participants now

5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing dexmedetomidine in Psychomotor Agitation, or all of them as a file.
02

Study summary

This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.

Read the detailed description

This is a Phase 1b/2 randomized, double-blind, placebo controlled, ascending dose finding study assessing efficacy, pharmacokinetics, safety, and tolerability of BXCL501 with 3 dosing groups in adult (65 years and older) males and females with acute agitation associated with all forms of dementia. Evaluation of three (3) doses of sublingual BXCL 501 are planned. Cohort 1, Cohort 2 and Cohort 3 will be given 30µg, 60µg and 90µg dose respectively of BXCL501 or placebo. Subjects assigned to Cohort 3 will participate in a 1-week safety observation before being enrolled.

This is an adaptive design as doses selected for testing may be different from these, based upon safety reviews. Doses lower or higher may be chosen to test, up to 180µg, and additional subjects may be added to a cohort. BXCL501 films may be divided in half if needed to deliver half-dose strengths. At least 30 subjects (10 per cohort) will be enrolled at up to 3 study sites in the United States. In Part B a total of 46 subjects will receive BXCL501 40 μg or matching placebo film.

The effects of BXCL 501 on acute agitation will be assessed by the following scales: Pittsburgh Agitation Scale (PAS), the PANSS-EC (PEC), Cohen-Mansfield Agitation Inventory (CMAI), CGI-Severity for Agitation and CGI Improvement for Agitation. Adverse Events (AEs), clinical laboratory tests, ECG, and vital signs will be monitored, and all observed.

03

Conditions studied

  • Agitation,Psychomotor
  • Dementia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 65 years and older.
  • Patients who have dementia and a history of acute agitation.
  • History of agitation that requires intervention or impairs social or daily activities
  • Patients who meet International Psychogeriatric Association (IPA) diagnostic criterion for agitation.
  • Patients with a total score of ≥ 8 on the Pittsburgh Agitation Scale (PAS).
  • Patients who have a score of ≥ 2 on at least 1 of the 4 items on the Pittsburgh Agitation Scale (PAS).
  • Patients who read, understand and provide written , or who have a Legally Authorized Representative (LAR).
  • Patients who are in good general health.

Exclusion criteria

Exclusion Criteria:

  • For Part B: Patients with dementia associated with Parkinson's disease and/or Lewy Body Disease, if etiology of dementia is known.
  • Patients with agitation caused by acute intoxication.
  • Patients treated within 4 hours prior to study drug administration with benzodiazepines, other sedatives, hypnotics or oral or short-acting intramuscular antipsychotics must be excluded.
  • Treatment with alpha-1 noradrenergic blockers, alpha adrenergic antagonists within 8 hours prior to dosing.
  • No new chronic medications initiated in the past 14 days prior to screening excluding over-the-counter products taken sporadically.
  • Patients at significant risk of harm to themselves or others
  • Patients considered medically unstable or in recovery
  • Patients with history of syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension.
  • Cohort 3 only: Patients who are taking nitrates or beta blockers shall be excluded. Any other anti-hypertensives should be maintained in the course of the study.
  • Patients who have received an drug within 30 days prior to the current agitation episode must be excluded.
  • Patients experiencing clinically significant pain, per Investigator.
  • Cohort 3 only: Patients who are a high fall risk assessed via the Johns Hopkins Fall Risk Assessment (total score >13) or during the 1-week safety observation period
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Cohort 1- 30 Micrograms

    Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo

    Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film

  • Active comparator
    Cohort 2- 60 Micrograms

    Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo. Additional 20 subjects receive 60 Micrograms or placebo.

    Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film

  • Active comparator
    Cohort 3- 90 Micrograms

    Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo

    Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film

  • Active comparator
    Part B Cohort

    Part B cohort consists 46 subjects receiving 40 Micrograms or placebo

    Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score

    The change in PEC score was evaluated at 2 hours following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.

    Time frame: Baseline and 2 hours post-dose

  2. Number of Patients With Adverse Events

    The safety and tolerability of single doses of BXCL501 was determined in treatment of acute agitation associated with dementia.

    Time frame: Day 7 post dose

Secondary outcomes

  1. Change in Pittsburgh Agitation Scale (PAS) Total Score From Baseline

    The onset and magnitude of calming effects of different doses of BXCL501 on symptoms of acute agitation associated with dementia was described as measured by the PAS. The PAS is an instrument that measured 4 behaviors namely: aberrant vocalization, motor agitation, aggressiveness and resisting to care. The patients are evaluated on a scale of 0 to 4, where 0 indicated no agitation and 4 indicated highest form of agitation. The PAS total score ranges from 0 to 16. Higher scores mean a worse outcome. Change in value of PAS total score, with negative value indicated the improvement in condition of the patients.

    Time frame: Baseline and at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, Day 3, Day 7 post-dose

  2. Changes in Agitation-Calmness Evaluation Scale (ACES) Score From Baseline

    To evaluate the change in the total score of ACES from baseline to 8 hours post administration of 30 mcg, 60 mcg and 40 mcg compared to placebo. The ACES is a single item measure rating overall agitation and sedation which ranges from 1 to 9, where 1 indicates marked agitation, 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable. Change from baseline (pre-dose) ACES total score, with negative values in favor of improvement.

    Time frame: Baseline and 1 hour, 2 hours, 4 hours, 8 hours post-dose

  3. Changes in Positive and Negative Syndrome Scale (PANSS) Excited Component (PEC) Total Score From Baseline

    The change in PEC score was evaluated following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.

    Time frame: Baseline and at 30 minutes, 1 hour, 4 hours, 8 hours, 24 hours, Day 3 and Day 7 post-dose

  4. Number of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders")

    The Number of patients who achieved a 40%reduction in total PEC score from baseline at 2 hours following administration of BXCL501 30 mcg, 60 mcg (for Part A) and BXCL501 40 mcg (for Part B) compared to placebo were evaluated. Responder defined as achieving \>= 40% reduction in PEC from baseline (pre-dose). The change from baseline in (pre-dose) PEC total score is presented for the Primary Outcome above.

    Time frame: Baseline and 2 hours post-dose

  5. Change in Clinician Global Impression of Severity (CGI-S) Agitation Score From Baseline

    The CGI-S was based upon the severity of agitation. It was assessed based on the following scale: 0 = Not assessed; 1 = Normal not at all symptomatic; 2 = Minimally symptomatic- few or mild symptoms -little interference with patients functioning; 3 = Mildly symptomatic-low level of symptoms-little interference in social functioning; 4 = Moderately symptomatic-some prominent symptoms-some interference in functioning; 5 = Markedly symptomatic-significant symptoms with very substantial interference in functioning; 6 = Severely symptomatic- very marked symptoms make it difficult for patients to engage with others; 7 = Among the most extremely symptomatic patients-extreme symptoms -patient is incapacitated or highly dangerous to self or others requires extra care and supervision. The higher the score, the higher is the severity of the agitation and lesser the score, the lower the agitation. Change from baseline CGIS total score, with negative values in favor of improvement.

    Time frame: Baseline and at 2 hours, and 24 hours post-dose

  6. Clinical Global Impression - Improvement (CGI-I) Agitation Score

    To evaluate the CGI-I agitation score at 30 minutes, 1 hour, 2 hours, and 8 hours after administration of 30 mcg, 60 mcg and 40 mcg of BXCL501 compared to placebo. The CGI-I scores range from 1 to 7 comprise of 0 = Not assessed (missing), 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The lower score (1) indicated the improvement in the condition of patient and higher score (7) indicates the worsening of the condition. Straight CGI-I total score, with lower values in favor of improvement.

    Time frame: 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours post-dose

  7. Change in Cohen Mansfield Agitation Inventory (CMAI) Total Score From Baseline

    To evaluate the change in Cohen Mansfield Agitation Inventory (CMAI) total score from baseline after 2 hour and on Day 7 post administration of 30 mcg, 60 mcg and 40 mcg BXCL501 compared to placebo. The CMAI is a rating which is comprised of 29 behaviors each rated on a 7-point scale of frequency. A total CMAI score is obtained by summing all the individual items, giving a range from 29 to 203. Change from baseline (pre-dose) CMAI total score, with negative values in favor of improvement in the condition of the patients.

    Time frame: Baseline and at 2 Hours and Day 7 post-dose

  8. Number of Patients With Event "Time Taken for Medication to Dissolve"

    To evaluate the time taken for BXCL501 30 mcg, 60mcg, 90 mcg and 40 mcg compared to placebo to dissolve which was measured after 30 minutes of administration.

    Time frame: At 30 minutes post-dose

  9. Number of Patients Showing Negative Reaction to Sublingual Film in the Examiner's Opinion

    To evaluate the number patient showing negative reactions to sublingual film by assessing the buccal at 30 minutes, 2 hours, 4 hours and 24 hours post administration of 30mcg, 60 mcg, 40 mcg and 90 mcg v/s placebo. The larger number of patients reporting negative reaction, the lesser is the reliability of the drug.

    Time frame: At 30 minutes, 2 hours, 4 hours, 24 hours post dose

  10. Part B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS)

    To evaluate the change in PANSS Supplementary Items Total Score from Baseline to 2 hours post administration of 40 mcg of BXCL501 compared to placebo. PANSS Supplementary Items: The total score (sum score of anger, difficulty in delaying gratification, and affective lability) ranges from 3 to 21. The higher score indicates the worsening of the condition and lower score indicates the improvement of the condition of the patient. Change from baseline (pre-dose) PANSS Supplementary Items total score, with negative values in favor of improvement.

    Time frame: Baseline and at 2 hours post-dose

07

Results

Posted Sep 21, 2023

Participant flow

The trial was conducted at 4 sites in the United States from 27 December 2019 to 24 January 2022.

Participant flow — Overall Study
MilestonePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
Started16204142323
Completed16154102223
Not completed050410
Withdrew: Covid 19 lockdown050400
Withdrew: Assisted living facility was closed000010

Outcome measures

PrimaryMean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score

The change in PEC score was evaluated at 2 hours following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.

Time frame:
Baseline and 2 hours post-dose
Reported as:
Mean · score on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score-5.4 ± 3.4-7.1 ± 3.8—-2.9 ± 2.7-6.8 ± 5.1-1.8 ± 4.4
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0813
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0011
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0002
PrimaryNumber of Patients With Adverse Events

The safety and tolerability of single doses of BXCL501 was determined in treatment of acute agitation associated with dementia.

Time frame:
Day 7 post dose
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events
ParticipantsPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
Number of Patients With Adverse Events111440122
SecondaryChange in Pittsburgh Agitation Scale (PAS) Total Score From Baseline

The onset and magnitude of calming effects of different doses of BXCL501 on symptoms of acute agitation associated with dementia was described as measured by the PAS. The PAS is an instrument that measured 4 behaviors namely: aberrant vocalization, motor agitation, aggressiveness and resisting to care. The patients are evaluated on a scale of 0 to 4, where 0 indicated no agitation and 4 indicated highest form of agitation. The PAS total score ranges from 0 to 16. Higher scores mean a worse outcome. Change in value of PAS total score, with negative value indicated the improvement in condition of the patients.

Time frame:
Baseline and at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, Day 3, Day 7 post-dose
Reported as:
Mean · score on a scale
Change in Pittsburgh Agitation Scale (PAS) Total Score From Baseline
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
30 minutes-1.3 ± 1.2-1.6 ± 1.7—-1.3 ± 1.6-1.3 ± 2.8-0.7 ± 0.9
1 hour-2.5 ± 1.8-4.0 ± 2.2—-2.1 ± 1.8-4.7 ± 3.2-1.6 ± 2.0
2 hours-3.9 ± 2.4-5.8 ± 2.1—-2.6 ± 2.4-5.4 ± 3.4-1.8 ± 2.7
4 hours-4.7 ± 3.1-6.4 ± 1.3—-3.3 ± 2.8-5.2 ± 3.7-2.1 ± 2.8
8 hours-4.4 ± 3.2-6.2 ± 1.7—-3.1 ± 2.0-4.1 ± 3.5-2.3 ± 2.7
24 hours-4.3 ± 2.8-4.9 ± 2.1—-3.9 ± 2.4-2.0 ± 2.2-1.8 ± 2.4
Day 3-3.9 ± 3.4-4.9 ± 2.4—-3.7 ± 3.4-2.0 ± 1.9-1.9 ± 1.6
Day 7-3.9 ± 3.1-4.3 ± 2.3—-3.3 ± 2.7-2.6 ± 3.3-1.1 ± 1.4
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.9616
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5460
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0961
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1359
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1688
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.6670
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.8695
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5002
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5631
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0089
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = <.0001
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0011
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0008
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.2847
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.2616
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1989
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.4585
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0005
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0004
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0025
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.1027
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.7953
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.1416
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0658
SecondaryChanges in Agitation-Calmness Evaluation Scale (ACES) Score From Baseline

To evaluate the change in the total score of ACES from baseline to 8 hours post administration of 30 mcg, 60 mcg and 40 mcg compared to placebo. The ACES is a single item measure rating overall agitation and sedation which ranges from 1 to 9, where 1 indicates marked agitation, 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable. Change from baseline (pre-dose) ACES total score, with negative values in favor of improvement.

Time frame:
Baseline and 1 hour, 2 hours, 4 hours, 8 hours post-dose
Reported as:
Mean · score on a scale
Changes in Agitation-Calmness Evaluation Scale (ACES) Score From Baseline
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
1 hour0.6 ± 0.61.1 ± 0.7—0.5 ± 0.51.8 ± 1.60.4 ± 0.8
2 hours0.9 ± 1.02.7 ± 1.6—0.9 ± 0.92.5 ± 1.90.7 ± 1.3
4 hours1.3 ± 1.02.7 ± 1.2—0.9 ± 1.12.4 ± 2.01.0 ± 1.4
8 hours1.4 ± 1.12.2 ± 0.9—0.9 ± 0.81.5 ± 1.51.0 ± 1.2
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.8760
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.9077
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.7208
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.3666
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0191
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0006
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = <.0001
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0003
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0006
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0002
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0029
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.2446
SecondaryChanges in Positive and Negative Syndrome Scale (PANSS) Excited Component (PEC) Total Score From Baseline

The change in PEC score was evaluated following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.

Time frame:
Baseline and at 30 minutes, 1 hour, 4 hours, 8 hours, 24 hours, Day 3 and Day 7 post-dose
Reported as:
Mean · score on a scale
Changes in Positive and Negative Syndrome Scale (PANSS) Excited Component (PEC) Total Score From Baseline
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
30 minutes-2.2 ± 1.6-1.7 ± 2.2—-0.6 ± 1.4-1.0 ± 2.4-1.0 ± 1.7
1 hours-3.6 ± 1.9-5.4 ± 3.6—-2.3 ± 2.0-5.7 ± 4.4-1.9 ± 3.2
4 hours-6.8 ± 4.4-8.1 ± 2.5—-4.1 ± 3.6-6.5 ± 4.5-2.8 ± 4.8
8 hours-7.1 ± 4.6-8.8 ± 3.1—-4.6 ± 3.3-5.0 ± 4.3-3.2 ± 4.7
Day 2; 24 hours-5.7 ± 4.0-6.0 ± 3.8—-4.3 ± 3.3-3.4 ± 3.7-2.4 ± 4.0
Day 3-5.3 ± 5.0-5.9 ± 4.2—-3.9 ± 3.7-3.2 ± 3.3-1.8 ± 2.7
Day 7-4.9 ± 3.9-4.6 ± 3.9—-3.4 ± 4.4-2.5 ± 4.1-1.5 ± 1.5
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0926
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.3976
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1169
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.3786
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5640
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.6020
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5875
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1055
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0024
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0016
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0002
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.2039
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1948
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.5615
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.8266
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0002
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0004
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.1037
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.3267
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0339
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.1892
SecondaryNumber of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders")

The Number of patients who achieved a 40%reduction in total PEC score from baseline at 2 hours following administration of BXCL501 30 mcg, 60 mcg (for Part A) and BXCL501 40 mcg (for Part B) compared to placebo were evaluated. Responder defined as achieving \>= 40% reduction in PEC from baseline (pre-dose). The change from baseline in (pre-dose) PEC total score is presented for the Primary Outcome above.

Time frame:
Baseline and 2 hours post-dose
Reported as:
Count of participants · Participants
Number of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders")
ParticipantsPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
Number of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders")414—192
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Fisher Exact · p = 0.3359
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Fisher Exact · p = 0.0004
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Fisher Exact · p = 0.0351
SecondaryChange in Clinician Global Impression of Severity (CGI-S) Agitation Score From Baseline

The CGI-S was based upon the severity of agitation. It was assessed based on the following scale: 0 = Not assessed; 1 = Normal not at all symptomatic; 2 = Minimally symptomatic- few or mild symptoms -little interference with patients functioning; 3 = Mildly symptomatic-low level of symptoms-little interference in social functioning; 4 = Moderately symptomatic-some prominent symptoms-some interference in functioning; 5 = Markedly symptomatic-significant symptoms with very substantial interference in functioning; 6 = Severely symptomatic- very marked symptoms make it difficult for patients to engage with others; 7 = Among the most extremely symptomatic patients-extreme symptoms -patient is incapacitated or highly dangerous to self or others requires extra care and supervision. The higher the score, the higher is the severity of the agitation and lesser the score, the lower the agitation. Change from baseline CGIS total score, with negative values in favor of improvement.

Time frame:
Baseline and at 2 hours, and 24 hours post-dose
Reported as:
Mean · score on a scale
Change in Clinician Global Impression of Severity (CGI-S) Agitation Score From Baseline
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
2 hours-1.3 ± 0.8-2.1 ± 0.9—-0.9 ± 0.9-2.2 ± 1.3-0.7 ± 1.0
24 hours-1.4 ± 1.1-1.6 ± 0.9—-1.2 ± 1.1-1.2 ± 1.1-0.7 ± 1.2
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0952
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.8977
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0002
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.3147
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = <.0001
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.1241
SecondaryClinical Global Impression - Improvement (CGI-I) Agitation Score

To evaluate the CGI-I agitation score at 30 minutes, 1 hour, 2 hours, and 8 hours after administration of 30 mcg, 60 mcg and 40 mcg of BXCL501 compared to placebo. The CGI-I scores range from 1 to 7 comprise of 0 = Not assessed (missing), 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The lower score (1) indicated the improvement in the condition of patient and higher score (7) indicates the worsening of the condition. Straight CGI-I total score, with lower values in favor of improvement.

Time frame:
30 minutes, 1 hour, 2 hours, 4 hours, 8 hours post-dose
Reported as:
Least squares mean · score on a scale
Clinical Global Impression - Improvement (CGI-I) Agitation Score
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
30 minutes3.3 ± 0.23.4 ± 0.2—3.5 ± 0.23.5 ± 0.13.7 ± 0.1
1 hour3.0 ± 0.22.6 ± 0.2—3.3 ± 0.22.5 ± 0.23.5 ± 0.2
2 hours2.4 ± 0.21.6 ± 0.2—3.2 ± 0.21.9 ± 0.23.6 ± 0.2
4 hours2.4 ± 0.31.5 ± 0.2—3.0 ± 0.32.0 ± 0.33.3 ± 0.3
8 hours2.3 ± 0.21.4 ± 0.2—3.0 ± 0.22.5 ± 0.33.5 ± 0.3
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.4080
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.4198
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0370
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.1324
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0624
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.6334
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0275
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = <.0001
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0001
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = <.0001
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.2806
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0002
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = <.0001
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0009
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0081
SecondaryChange in Cohen Mansfield Agitation Inventory (CMAI) Total Score From Baseline

To evaluate the change in Cohen Mansfield Agitation Inventory (CMAI) total score from baseline after 2 hour and on Day 7 post administration of 30 mcg, 60 mcg and 40 mcg BXCL501 compared to placebo. The CMAI is a rating which is comprised of 29 behaviors each rated on a 7-point scale of frequency. A total CMAI score is obtained by summing all the individual items, giving a range from 29 to 203. Change from baseline (pre-dose) CMAI total score, with negative values in favor of improvement in the condition of the patients.

Time frame:
Baseline and at 2 Hours and Day 7 post-dose
Reported as:
Mean · score on a scale
Change in Cohen Mansfield Agitation Inventory (CMAI) Total Score From Baseline
score on a scalePart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A-90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
2 hours-8.9 ± 5.1-14.7 ± 9.8—1.6 ± 4.5-17.9 ± 22.7-5.7 ± 14.0
Day 7-5.9 ± 4.3-6.6 ± 6.7—0.4 ± 9.8-6.9 ± 17.7-1.4 ± 4.5
Statistical analysis
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0591
  • Part A-30 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0966
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = <.0001
  • Part A-60 mcg BXCL501 vs Part A-Placebo · Mixed effects model · p = 0.0290
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0937
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.2747
SecondaryNumber of Patients With Event "Time Taken for Medication to Dissolve"

To evaluate the time taken for BXCL501 30 mcg, 60mcg, 90 mcg and 40 mcg compared to placebo to dissolve which was measured after 30 minutes of administration.

Time frame:
At 30 minutes post-dose
Reported as:
Count of participants · Participants
Number of Patients With Event "Time Taken for Medication to Dissolve"
ParticipantsPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
1- 30 seconds000000
31- 59 seconds000002
1- 2 minutes108281210
3+ minutes612261111
SecondaryNumber of Patients Showing Negative Reaction to Sublingual Film in the Examiner's Opinion

To evaluate the number patient showing negative reactions to sublingual film by assessing the buccal at 30 minutes, 2 hours, 4 hours and 24 hours post administration of 30mcg, 60 mcg, 40 mcg and 90 mcg v/s placebo. The larger number of patients reporting negative reaction, the lesser is the reliability of the drug.

Time frame:
At 30 minutes, 2 hours, 4 hours, 24 hours post dose
Reported as:
Count of participants · Participants
Number of Patients Showing Negative Reaction to Sublingual Film in the Examiner's Opinion
ParticipantsPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
30 minutes Post dose000000
2 hours post dose000000
4 hours post dose000000
24 hours post dose000000
SecondaryPart B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS)

To evaluate the change in PANSS Supplementary Items Total Score from Baseline to 2 hours post administration of 40 mcg of BXCL501 compared to placebo. PANSS Supplementary Items: The total score (sum score of anger, difficulty in delaying gratification, and affective lability) ranges from 3 to 21. The higher score indicates the worsening of the condition and lower score indicates the improvement of the condition of the patient. Change from baseline (pre-dose) PANSS Supplementary Items total score, with negative values in favor of improvement.

Time frame:
Baseline and at 2 hours post-dose
Reported as:
Mean · score on a scale
Part B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS)
score on a scalePart B-40 Mcg-BXCL501Part B-Placebo
Part B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS)-3.7 ± 2.9-0.6 ± 2.3
Statistical analysis
  • Part B-40 Mcg-BXCL501 vs Part B-Placebo · Mixed effects model · p = 0.0002

Adverse events

Collected over Day 7 post-dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A-30 mcg BXCL5010/16 (0%)0/16 (0%)11/16 (68.8%)
Part A-60 mcg BXCL5010/20 (0%)0/20 (0%)14/20 (70%)
Part A- 90 mcg BXCL5010/4 (0%)0/4 (0%)4/4 (100%)
Part A-Placebo0/14 (0%)0/14 (0%)0/14 (0%)
Part B-40 Mcg-BXCL5011/23 (4.3%)1/23 (4.3%)12/23 (52.2%)
Part B-Placebo0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent serious events
Most frequent serious events
EventPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
SepsisInfections and infestations0/160/200/40/141/230/23
HypernatraemiaMetabolism and nutrition disorders0/160/200/40/141/230/23
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPart A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-Placebo
SomnolenceNervous system disorders9/1612/203/40/148/232/23
Orthostatic hypotensionVascular disorders1/161/203/40/140/230/23
DizzinessNervous system disorders1/161/202/40/141/230/23
HypotensionVascular disorders0/162/201/40/142/230/23
DehydrationMetabolism and nutrition disorders0/160/200/40/143/230/23
HeadacheNervous system disorders0/161/200/40/140/230/23
BradycardiaCardiac disorders0/161/200/40/140/230/23
Dry mouthGastrointestinal disorders0/161/200/40/141/230/23
NauseaGastrointestinal disorders0/161/200/40/141/230/23
VomitingGastrointestinal disorders0/160/200/40/141/230/23

Baseline characteristics

The safety population consisted of all patients who received study drug.

Age, Continuous
Age, Continuous(Years)Part A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-PlaceboTotal
Mean75.8 ± 8.077.7 ± 6.468.8 ± 7.975.9 ± 8.977.4 ± 8.277.3 ± 8.676.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Part A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-PlaceboTotal
Female5100881142
Male111046151258
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-PlaceboTotal
Hispanic or Latino02008717
Not Hispanic or Latino1618414151683
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A-30 mcg BXCL501Part A-60 mcg BXCL501Part A- 90 mcg BXCL501Part A-PlaceboPart B-40 Mcg-BXCL501Part B-PlaceboTotal
American Indian or Alaska Native0000000
Asian0000101
Native Hawaiian or Other Pacific Islander0000000
Black or African American36315523
White1314113171876
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

5 sites
  • BioXcel Clinical Research Site
    Homestead, Florida 33032, United States
  • BioXcel Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • BioXcel Clinical Research Site
    Springfield, Massachusetts 01103, United States
  • BioXcel Clinical Research Site
    Caro, Michigan 48723, United States
  • BioXcel Clinical Research Site
    Toms River, New Jersey 08755, United States
09

References and documents

Publications

  • Persson NDA, Uusalo P, Nedergaard M, Lohela TJ, Lilius TO. Could dexmedetomidine be repurposed as a glymphatic enhancer? Trends Pharmacol Sci. 2022 Dec;43(12):1030-1040. doi: 10.1016/j.tips.2022.09.007. Epub 2022 Oct 21. PubMed 36280451 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2022, 24 months.

Results were first posted in Sep 2023, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2020
First posted
Feb 5, 2020
StartActual
Dec 27, 2019
Primary completionActual
Jan 24, 2022
CompletionActual
Jan 24, 2022
Results first posted
Sep 21, 2023
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04251910
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Dec 27, 2019
Primary completion
Jan 24, 2022
Completion
Jan 24, 2022
Results posted
Sep 21, 2023
Last update
Aug 11, 2026

Study contacts

BioXcel MM, MD
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion